Amphastar Pharmaceuticals Cash Flow from Operating Activities 2012-2024 | AMPH
Amphastar Pharmaceuticals cash flow from operating activities from 2012 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
Amphastar Pharmaceuticals Annual Cash Flow Ops
(Millions of US $) |
| 2024 |
$213 |
| 2023 |
$184 |
| 2022 |
$89 |
| 2021 |
$98 |
| 2020 |
$57 |
| 2019 |
$42 |
| 2018 |
$38 |
| 2017 |
$39 |
| 2016 |
$39 |
| 2015 |
$11 |
| 2014 |
$21 |
| 2013 |
$31 |
| 2012 |
$-2 |
| 2011 |
$19 |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.553B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
